Fairtree Asset Management Pty Ltd Buys Shares of 7,556 Stryker Corporation $SYK

Fairtree Asset Management Pty Ltd bought a new stake in Stryker Corporation (NYSE:SYK) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 7,556 shares of the medical technology company’s stock, valued at approximately $2,379,000. Stryker accounts for approximately 0.9% of Fairtree Asset Management Pty Ltd’s investment portfolio, making the stock its 27th largest holding.

Several other hedge funds have also recently modified their holdings of the stock. VanderPol Investments L.L.C. raised its position in Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after buying an additional 28 shares during the last quarter. KCM Investment Advisors LLC boosted its holdings in shares of Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after acquiring an additional 28 shares in the last quarter. Rossby Financial LCC increased its stake in shares of Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after acquiring an additional 28 shares during the period. Tcfg Wealth Management LLC raised its holdings in Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares in the last quarter. Finally, West Michigan Advisors LLC raised its holdings in Stryker by 0.4% during the fourth quarter. West Michigan Advisors LLC now owns 7,468 shares of the medical technology company’s stock worth $2,631,000 after purchasing an additional 30 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

NYSE SYK opened at $327.97 on Friday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The company has a market capitalization of $125.80 billion, a P/E ratio of 33.99, a PEG ratio of 2.17 and a beta of 0.76. The business has a 50 day moving average price of $326.64 and a 200 day moving average price of $332.66. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is presently 36.48%.

Insider Buying and Selling at Stryker

In related news, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 665,370 shares of company stock valued at $216,238,501 over the last quarter. Corporate insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SYK. Argus set a $370.00 price objective on Stryker in a report on Thursday, July 9th. Citizens Jmp cut their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research note on Monday, August 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. Wolfe Research downgraded Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Finally, Barclays cut their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.